All In Biotech

Drug Trial Radar · NCT06361186

Proximod Pharmacokinetics In Healthy Subjects

A Single-center, Randomized, Double-blind, Placebo-controlled Phase I Study to Evaluate the Tolerability, Pharmacokinetics and Pharmacodynamics of Proximod in Healthy Subjects.

Last checked: Nov 19, 2026Latest source record: Apr 11, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 134 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

134

Actual

Start

Sep 14, 2017

Primary completion

Nov 1, 2017

Study completion Jun 22, 2021

Sponsor

Lead sponsor
Longevity Inc.Industry
Sponsor type
Industry
First posted
Apr 11, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 50 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to evaluate the tolerability, pharmacokinetics and pharmacodynamics of Proximod in healthy subjects. The main questions it arms to answer are: 1. to evaluate the safety and tolerance of Proximod in healthy subjects after single or repeated doses. 2. to learn the pharmacodynamics of Proximod in healthy subjects after single or repeated doses. 3. to evaluation of the effect of food on the pharmacokinetics of Proximod in healthy subjects Participants will receive test tablets or placebo at the indicated date and collect blood samples.

Conditions

  • Rheumatoid Arthritis

Interventions

  • ProximodDrug

    Single and multiple-dose to establish the safety and PK profile

  • PlaceboDrug

    Placebo controlled

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Peak plasma concentration (Cmax)Time frame: Up to 64 days
  2. Time to peak plasma concentration (Tmax)Time frame: Up to 64 days
  3. The lowest plasma concentration (Cmin)Time frame: Up to 64 days
  4. Half-life (t1/2)Time frame: Up to 64 days
  5. Number of adverse events and number of participants with adverse eventsTime frame: Up to 64 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The first hospital of Jilin University

    Changchun, Jilin, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.